Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma

[1]  D. Tenen,et al.  Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines. , 2021, Gene.

[2]  H. Komori,et al.  Runx2 is essential for the transdifferentiation of chondrocytes into osteoblasts , 2020, PLoS genetics.

[3]  Kosei Ito,et al.  Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation , 2020, Molecules and cells.

[4]  J. Bushweller.  Targeting transcription factors in cancer — from undruggable to reality , 2019, Nature Reviews Cancer.

[5]  D. Herranz,et al.  The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer. , 2018, Trends in cancer.

[6]  J. Dekker,et al.  CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia , 2018, Cell.

[7]  Howard Y. Chang,et al.  Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element , 2018, Cell.

[8]  Jia Gu,et al.  fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.

[9]  A. Tanay,et al.  Multiscale 3D Genome Rewiring during Mouse Neural Development , 2017, Cell.

[10]  Y. Kaneda,et al.  Genetic regulation of the RUNX transcription factor family has antitumor effects , 2017, The Journal of clinical investigation.

[11]  Dmitriy Sonkin,et al.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.

[12]  Mazhar Adli,et al.  Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers , 2016, EBioMedicine.

[13]  Fidel Ramírez,et al.  deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..

[14]  Yunlong He,et al.  A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells , 2016, PLoS genetics.

[15]  C. Bonaïti‐pellié,et al.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Wood,et al.  RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma , 2015, Cell.

[17]  Howard H. Yang,et al.  p53 Loss Increases the Osteogenic Differentiation of Bone Marrow Stromal Cells , 2015, Stem cells.

[18]  S. Takeda,et al.  Loss of Osteoblast Runx3 Produces Severe Congenital Osteopenia , 2015, Molecular and Cellular Biology.

[19]  Yoshiaki Ito,et al.  The RUNX family: developmental regulators in cancer , 2015, Nature Reviews Cancer.

[20]  Howard Y. Chang,et al.  ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.

[21]  A. V. van Wijnen,et al.  RUNX3 Facilitates Growth of Ewing Sarcoma Cells , 2014, Journal of cellular physiology.

[22]  David M. Thomas,et al.  Translational biology of osteosarcoma , 2014, Nature Reviews Cancer.

[23]  L. Zender,et al.  Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles , 2014, Nature.

[24]  D. Felsher,et al.  MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.

[25]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[26]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[27]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[28]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[29]  Yoshiaki Ito,et al.  RUNX family: Regulation and diversification of roles through interacting proteins , 2013, International journal of cancer.

[30]  R. Young,et al.  Transcriptional Regulation and Its Misregulation in Disease , 2013, Cell.

[31]  W. Reinhold,et al.  Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction , 2012, Proceedings of the National Academy of Sciences.

[32]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[33]  David S. Lapointe,et al.  Genomic Promoter Occupancy of Runt-related Transcription Factor RUNX2 in Osteosarcoma Cells Identifies Genes Involved in Cell Adhesion and Motility* , 2011, The Journal of Biological Chemistry.

[34]  G. Stein,et al.  The Role of RUNX2 in Osteosarcoma Oncogenesis , 2010, Sarcoma.

[35]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[36]  A. Nakagawara,et al.  RUNX3 Modulates DNA Damage-mediated Phosphorylation of Tumor Suppressor p53 at Ser-15 and Acts as a Co-activator for p53* , 2010, The Journal of Biological Chemistry.

[37]  O. Myklebost,et al.  Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort , 2010, Genes, chromosomes & cancer.

[38]  M. Bouxsein,et al.  Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage , 2008, Proceedings of the National Academy of Sciences.

[39]  F. Alt,et al.  Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.

[40]  D. Littman,et al.  Repression of interleukin-4 in T helper type 1 cells by Runx/Cbfβ binding to the Il4 silencer , 2007, The Journal of experimental medicine.

[41]  M. Salto‐Tellez,et al.  RUNX3, A Novel Tumor Suppressor, Is Frequently Inactivated in Gastric Cancer by Protein Mislocalization , 2005 .

[42]  D. Levanon,et al.  Structure and regulated expression of mammalian RUNX genes , 2004, Oncogene.

[43]  D. Littman,et al.  Differential Requirements for Runx Proteins in CD4 Repression and Epigenetic Silencing during T Lymphocyte Development , 2002, Cell.

[44]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[45]  S. Itohara,et al.  Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer , 2002, Cell.

[46]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[47]  P. Picci,et al.  C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression , 1998, Oncology.

[48]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[49]  E. Wagner,et al.  Osteoblasts are target cells for transformation in c-fos transgenic mice , 1993, The Journal of cell biology.

[50]  S. Holden,et al.  A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families. , 1992, The Journal of bone and joint surgery. British volume.

[51]  D. Lane,et al.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others , 2018, Nature Reviews Clinical Oncology.

[52]  N. Speck,et al.  RUNX Proteins in Development and Cancer , 2017 .

[53]  Yoshiaki Ito,et al.  Roles of RUNX in Solid Tumors. , 2017, Advances in experimental medicine and biology.

[54]  I. Wierstra,et al.  The c-myc promoter: still MysterY and challenge. , 2008, Advances in cancer research.

[55]  M. Salto‐Tellez,et al.  RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. , 2005, Cancer research.

[56]  F. Alt,et al.  Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. , 2001, Immunity.